Several randomized, controlled, phase III trials have evaluated the utility of antisense Bcl-2 combined with standard chemotherapy for the treatment of patients with chronic lymphocytic leukemia, multiple myeloma, malignant melanoma, or non-small cell lung carcinoma (8). This evidence concerns the gene BCL2 and plasma cell myeloma.